Chronic tolerance to recreational MDMA (3,4-methylenedioxymethamphetamine) or Ecstasy
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
This review of chronic tolerance to MDMA (3,4-methylenedioxymetamphetamine) covers the empirical data on dosage escalation, reduced subjective efficacy and bingeing in recreational Ecstasy users. Novice users generally take a single Ecstasy tablet, regular users typically take 2-3 tablets, whereas the most experienced users may take 10-25 tablets in a single session. Reduced subjective efficacy following repeated usage is typically described, with many users subjectively reporting the development of tolerance. Intensive self-administration or bingeing is often noted by experienced users. This can comprise ‘stacking’ on several tablets together, and ‘boosting’ on successive doses over an extended period. Some experienced users snort Ecstasy powder nasally, whereas a small minority inject MDMA. Chronic tolerance and bingeing are statistically linked to higher rates of drug-related psychobiological problems. In terms of underlying mechanisms, neuroadaptive processes are certainly involved, but there is a paucity of evidence on hepatic and behavioural mechanisms. Further studies specifically designed to investigate chronic tolerance, involving low intermittent dose regimens, are required. Most animal research has involved intensive MDMA dosing regimens designed to engender serotonergic neurotoxicity, and this may comprise another underlying mechanism. If distal serotonin axon terminal loss was also developing in recreational users, it may help to explain why reducing subjective efficacy, dosage escalation and increasing psychobiological problems often develop in parallel. In conclusion, there is extensive evidence for chronic pharmacodynamic tolerance to recreational Ecstasy/MDMA, but the underlying mechanisms are currently unclear. Several traditional processes are probably involved, but one of the possible causes is a novel mechanism largely unique to the ring substituted amphetamine derivatives, namely serotonergic neurotoxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Pharmacology and Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”)
Green, A. R., Mechan, A. O., Elliott, J. M., O’Shea, E., & Colado, M. I. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.3.3 · Cited by 1,272
Vollenweider, F. X., Gamma, A., Liechti, M., & Huber, T. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00013-x · Cited by 448 · cited 1×
“The pharmacodynamic effects of single doses of MDMA have been investigated in a number of placebo-controlled studies using human volunteers (Vollenweider et al., 1998; Liechti and Vollenweider, 2001).”
BackgroundSubjective Reports of the Effects of MDMA in a Clinical Setting
Greer, G., & Tolbert, R. (1986) · Journal of Psychoactive Drugs · doi:10.1080/02791072.1986.10472364 · Cited by 413
Gender differences in the subjective effects of MDMA
Liechti, M. E., Gamma, A., & Vollenweider, F. X. (2001) · Psychopharmacology · doi:10.1007/s002130000648 · Cited by 360
Liechti, M. E., & Vollenweider, F. X. (2001) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.348 · Cited by 236
(±)3,4-Methylenedioxymethamphetamine (‘Ecstasy’)-Induced Serotonin Neurotoxicity: Clinical Studies
McCann, U. D., Eligulashvili, V., & Ricaurte, G. A. (2000) · Neuropsychobiology · doi:10.1159/000026665 · Cited by 190 · cited 2×
“…psychological and physiological effects of MDMA are reviewed in more detail elsewhere (Steele et al., 1994; Green et al., 1995; McCann et al., 1996; Hegadoren et al., 1998; McCann et al., 2000; Morgan, 2000; Parrott, 2000; Kalant, 2001; Parrott, 2001; Cole and Sumnall, 2003a;b; Green et al., 2003).”
BackgroundMDMA (“ecstasy”) abuse: Psychopathological features and craving for chocolate: A case series
Schifano, F., & Magni, G. (1994) · Biological Psychiatry · doi:10.1016/0006-3223(94)90088-4 · Cited by 58
Cited by
Clinical applications of hallucinogens: a review
Garcia-Romeu, A., Kersgaard, B., & Addy, P. H. (2016) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000084 · Cited by 201
Distinct neural mechanisms for the prosocial and rewarding properties of MDMA
Heifets, B. D., Salgado, J. S., Taylor, M. D., Hoerbelt, P., Cardozo Pinto, D. F., Steinberg, E. E., Walsh, J. J., Sze, J. Y., & Malenka, R. C. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw6435 · Cited by 120
Dark Classics in Chemical Neuroscience: 3,4-Methylenedioxymethamphetamine
Dunlap, L. E., Andrews, A. M., & Olson, D. E. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00155 · Cited by 106
Mechan, A., Yuan, J., Hatzidimitriou, G., Irvine, R. J., McCann, U. D., & Ricaurte, G. A. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300808 · Cited by 67
“This particular repeated dosing regimen of MDMA was employed in order to simulate a common human recreational MDMA use pattern (Weir, 2000; Irvine et al, 2003; Parrott, 2005).”
BackgroundMethodInfluentialSchenk, S., & Highgate, Q. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15348 · Cited by 48
“…MDMA despite adverse consequences (Cottler et al.,. ,2001, 2009; Yen & Hsu, 2007), (4) tolerance to the positive effects (Kirkpatrick et al., 2012; Parrott, 2005; Peroutka et al., 1988; Yen & Hsu, 2007) and (5) development of withdrawal symptoms (Curran & Travill, 1997; McKetin et al., 2014;…”
Background
Metadata
- Authors
- Parrott, A. C.
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2005-01
- Volume
- 19
- Issue
- 1
- Pages
- 71-83
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2093527826
- Cited by
- 238
- References
- 7
- FWCI
- 18.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Chronic tolerance to recreational MDMA (3,4-methylenedioxymethamphetamine) or Ecstasy. https://app.cochat.ai/papers/10.1177/0269881105048900
- The paper
- Parrott, A. C. (2005). Chronic tolerance to recreational MDMA (3,4-methylenedioxymethamphetamine) or Ecstasy. Journal of Psychopharmacology. https://doi.org/10.1177/0269881105048900
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.